gms | German Medical Science

130. Kongress der Deutschen Gesellschaft für Chirurgie

Deutsche Gesellschaft für Chirurgie

30.04. - 03.05.2013, München

Article

Send article

Activated Leukocyte Cell Adhesion Molecule (CD166); A Cancer Stem Cell Marker for Non-Small Cell Lung Cancer?

Meeting Abstract

Search Medline for

  • Michael Tachezy - Universitätsklinikum Hamburg-Eppendorf, Allgemein-, Viszeral- und Thoraxchirurgie, Hamburg

Deutsche Gesellschaft für Chirurgie. 130. Kongress der Deutschen Gesellschaft für Chirurgie. München, 30.04.-03.05.2013. Düsseldorf: German Medical Science GMS Publishing House; 2013. Doc13dgch158

doi: 10.3205/13dgch158, urn:nbn:de:0183-13dgch1583

Published: April 26, 2013

© 2013 Tachezy.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.

Outline

Text

Introduction: Recently, the activated leukocyte cell adhesion molecule (ALCAM, CD166) was identified as an inert cancer stem cell marker for non-small cell lung cancer (NSCLC). Few data exist regarding the clinical relevance of CD166 expression in NSCLC.

Material and methods: Here, we evaluate the expression of CD166 using immunohistochemistry (clone MOG/07) in a large cohort of NSCLC patients (n=1910) on a tissue microarray basis. Results were correlated with clinical, histopathological, and patient survival data (Chi-square-test, t-test, Kaplan-Meier analysis, log-rank test, respectively). Multivariate analysis was also performed (Cox-regression).

Results: We found that CD166 is expressed in a large fraction of NSCLC (39%) and the expression is inversely associated with tumor size (p=0.041) and lymph node status (p=0.040). Tumor grading slightly failed to be significantly inverse associated with CD166 expression (p=0.054). Kaplan-Meier survival analysis revealed no significant overall survival benefit in the group of CD166-positive patients (p=0.099).

Conclusion: Due to the results of the present study, the theory of an ‘inert surface marker’ must be questioned. The association of CD166 with smaller tumors and no lymph node metastases does not make it a typical cancer stem cell marker. Further studies are required investigating the functional role of CD166 in NSCLC.